Cabergoline Tablet
FDA Label NDC 0093-5420

29 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Cabergoline (NDC 0093-5420). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 recommended evaluation before initiating cabergoline tablets, 2.2 recommended dosage, 3 dosage forms and strengths, 4 contraindications, 5.1 cardiac valvulopathy and pericardial fibrosis, 5.2 pleural, pulmonary and retroperitoneal fibrosis, 5.3 orthostatic hypotension, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.